Latest News

Semaglutide 2.4 mg Achieves 63% MASH Resolution in Phase 3 ESSENCE Trial
Written by: Radcliffe CVRM
Semaglutide 2.4mg Achieves 63% MASH Resolution in Phase 3 ESSENCE Trial
Written by: Radcliffe CVRM
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors Offer Enhanced Kidney Protection, Especially in…
Study Finds Multimorbidity Dramatically Increases Mortality Risk in Heart Failure Patients with Mildly Reduced and Preserved Ejection Fraction
Written by: Radcliffe CVRM
Study Finds Multimorbidity Dramatically Increases Mortality Risk in Heart Failure Patients with Mildly…
Written by: Radcliffe CVRM
GLP-1 Receptor Agonists Reduce Risks of Dementia, Cardiovascular Disease, and Psychiatric Disorders:…
Liver Disease: Efruxifermin Showed 39% Cirrhosis Reversal in MASH Patients in the Phase 2b SYMMETRY Study
Written by: Radcliffe CVRM
Liver Disease: Efruxifermin Showed 39% Cirrhosis Reversal in MASH Patients in the Phase 2b SYMMETRY Study
Serum Uric Acid as an Independent Predictor of Non-Alcoholic Fatty Liver Disease in Non-Obese Young Adults
Written by: Radcliffe CVRM
Serum Uric Acid as an Independent Predictor of Non-Alcoholic Fatty Liver Disease in Non-Obese Young…
Late-Breaking Trail and Featured Clinical Research Presentations Revealed for ACC Scientific Sessions 2025
Written by: ACC 2025
Late-Breaking Trial and Featured Clinical Research Presentations Revealed for ACC Scientific Sessions…
BPROAD: Promising Results for Intensive Blood Pressure Control in Type 2 Diabetes Patients
Written by: Radcliffe CVRM
BPROAD: Promising Results for Intensive Blood Pressure Control in Type 2 Diabetes Patients
AHA 24: PALISADE Trial Shows Promise for Patients with Familial Chylomicronemia Syndrome
Written by: Radcliffe Cardiology
AHA 24: PALISADE Trial Shows Promise for Patients with Familial Chylomicronemia Syndrome
ATTRibute-CM Open-Label Extension (OLE) Study: Sustained Benefits of Acoramidis in ATTR-CM
Written by: Radcliffe Cardiology
ATTRibute-CM Open-Label Extension (OLE) Study: Sustained Benefits of Acoramidis in ATTR-CM

External news

Written by: Medscape
Early Smartphone-Activated Bystander CPR Can Boost Survival
Written by: Medscape
Cardiac Risk Warning for Lamotrigine Challenged
Written by: Cardiac Vascular News
InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke
Written by: Medscape
Add-On Simvastatin Shows No Benefit in Depression
Written by: Cardiac Vascular News
Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
Written by: Medscape
Weight-Loss Drugs Show Promise but Remain Hard to Access
Written by: Cardiac Vascular News
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
Written by: Cardiac Vascular News
ITM to Provide COMPETE Trial Insights at SNMMI 2025 Annual Meeting in Oral Presentation and Satellite Symposium
Written by: Cardiac Vascular News
Viz.ai Receives First and Only FDA 510(k) Clearance for Subdural Measurements
Written by: Medscape
What Your Breathing Says About Your Mental Health